(Q37082042)

18 August 2017

1 reference

title

Why should we use multifunctional neuroprotective and neurorestorative drugs for Parkinson's disease? (English)

1 reference

18 August 2017

1 reference

1

Moussa B H Youdim

1 reference

PubMed ID

18267251

18 August 2017

Cornelis J Van der Schyf

series ordinal

3

object named as

Cornelis J Van der Schyf

1 reference

18 August 2017

Werner J Geldenhuys

2

1 reference

PubMed ID

18267251

18 August 2017

language of work or name

1 reference

1 January 2007

1 reference

Parkinsonism and Related Disorders

18 August 2017

1 reference

18 August 2017

13 Suppl 3

1 reference

18 August 2017

S281-91

1 reference

Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein

18 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Parkinson's disease. Second of two parts

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Parkinson's disease. First of two parts

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Neuroprotective strategies for Parkinson's disease: conceptual limits of animal models and clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Neuroprotective strategies in Parkinson's disease : an update on progress

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Parkinson's disease, pesticides and individual vulnerability

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Neuroprotection in Parkinson's disease: clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Neuroprotective effects of the dopamine D2/D3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Pramipexole. A review of its use in the management of early and advanced Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Memantine: a pharmacoeconomic review of its use in moderate-to-severe Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Multi-target therapeutics: when the whole is greater than the sum of the parts

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

From magic bullets to designed multiple ligands

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Designed multiple ligands. An emerging drug discovery paradigm

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Multifunctional neuroprotective drugs targeting monoamine oxidase inhibition, iron chelation, adenosine receptors, and cholinergic and glutamatergic action for neurodegenerative diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

CNS Targets for multi-functional drugs in the treatment of Alzheimer's and Parkinson's diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of tradi

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

LY227942, an inhibitor of serotonin and norepinephrine uptake: biochemical pharmacology of a potential antidepressant drug

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

MAO-B inhibitors: multiple roles in the therapy of neurodegenerative disorders?

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Rasagiline Mesylate, a New Mao-B Inhibitor for the Treatment of Parkinson's Disease: A Double-Blind Study as Adjunctive Therapy to Levodopa

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline: a potent, selective, and irreversible monoamine oxidase type B inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-B.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Effect of TV3326, a novel monoamine-oxidase cholinesterase inhibitor, in rat models of anxiety and depression

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Attenuation of MPTP-induced dopaminergic neurotoxicity by TV3326, a cholinesterase-monoamine oxidase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

(-)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Pharmacological aspects of (-)-deprenyl

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Selegiline is neuroprotective in primary brain cultures treated with 1-methyl-4-phenylpyridinium

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Protective effect of L-deprenyl against apoptosis induced by okadaic acid in cultured neuronal cells

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Neuroprotection by deprenyl and other propargylamines: glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Three-dimensional structure of human monoamine oxidase A (MAO A): relation to the structures of rat MAO A and human MAO B

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

N-Propargylamine protects SH-SY5Y cells from apoptosis induced by an endogenous neurotoxin, N-methyl(R)salsolinol, through stabilization of mitochondrial membrane and induction of anti-apoptotic Bcl-2.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

(-)-Deprenyl protects human dopaminergic neuroblastoma SH-SY5Y cells from apoptosis induced by peroxynitrite and nitric oxide

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Iron, brain ageing and neurodegenerative disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Therapeutic targets and potential of the novel brain- permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Novel neuroprotective mechanism of action of rasagiline is associated with its propargyl moiety: interaction of Bcl-2 family members with PKC pathway

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Monoamine oxidase-B inhibition in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Differential age-related changes of MAO-A and MAO-B in mouse brain and peripheral organs.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Biphasic and region-specific MAO-B response to aging in normal human brain.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Recent developments in the drug treatment of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Does caffeine intake protect from Alzheimer's disease?

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Neuroprotection by caffeine and adenosine A2A receptor blockade of beta-amyloid neurotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Caffeine reverses age-related deficits in olfactory discrimination and social recognition memory in rats. Involvement of adenosine A1 and A2A receptors.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Inhibition of monoamine oxidase B by selective adenosine A2A receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

8-(3-Chlorostyryl)caffeine may attenuate MPTP neurotoxicity through dual actions of monoamine oxidase inhibition and A2A receptor antagonism

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Monoamine oxidase B inhibition and neuroprotection: studies on selective adenosine A2A receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

NMDA receptor pathways as drug targets

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Potential role of neuroprotective agents in the treatment of patients with acute ischemic stroke

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

New targets for pharmacological intervention in the glutamatergic synapse

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

TNF alpha potentiates glutamate neurotoxicity by inhibiting glutamate uptake in organotypic brain slice cultures: neuroprotection by NF kappa B inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Neuroprotective effects of MK-801 in different rat stroke models for permanent middle cerebral artery occlusion: adverse effects of hypothalamic damage and strategies for its avoidance

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Animal models of stroke: do they have value for discovering neuroprotective agents?

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Reduction of edema and infarction by Memantine and MK-801 after focal cerebral ischaemia and reperfusion in rat

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Characterization of NGP 1-01, an aromatic polycyclic amine, as a calcium antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Structure-activity relationships of pentacycloundecylamines at the N-methyl-d-aspartate receptor.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

NGP1-01 is a brain-permeable dual blocker of neuronal voltage- and ligand-operated calcium channels.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

NGP1-01, a lipophilic polycyclic cage amine, is neuroprotective in focal ischemia

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Dopamine reuptake inhibition and failure to evoke dyskinesia in MPTP-treated primates

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Selective effects of cyclodiene insecticides on dopamine release in mammalian synaptosomes

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Synthesis and biological evaluation of pentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecane derivatives as potential therapeutic agents in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Screening of novel pentacyclo-undecylamines for neuroprotective activity

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Neurological mechanisms of green tea polyphenols in Alzheimer's and Parkinson's diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Metal chelation of polyphenols

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Studies on protective mechanisms of four components of green tea polyphenols against lipid peroxidation in synaptosomes

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Antioxidant and iron-chelating activities of the flavonoids catechin, quercetin and diosmetin on iron-loaded rat hepatocyte cultures

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Reversing the deleterious effects of aging on neuronal communication and behavior: beneficial properties of fruit polyphenolic compounds

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Multifunctional activities of green tea catechins in neuroprotection. Modulation of cell survival genes, iron-dependent oxidative stress and PKC signaling pathway

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Green tea catechins as brain-permeable, natural iron chelators-antioxidants for the treatment of neurodegenerative disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Green tea polyphenol (-)-epigallocatechin-3-gallate induces neurorescue of long-term serum-deprived PC12 cells and promotes neurite outgrowth

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Effects of pH and metal ions on antioxidative activities of catechins

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Protective effects of tea polyphenols against oxidative damage to red blood cells

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Neuroprotection and neurorescue against Abeta toxicity and PKC-dependent release of nonamyloidogenic soluble precursor protein by green tea polyphenol (-)-epigallocatechin-3-gallate

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Reduction of iron-regulated amyloid precursor protein and beta-amyloid peptide by (-)-epigallocatechin-3-gallate in cell cultures: implications for iron chelation in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Metal and inflammatory targets for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

Drug Discovery Targeted to the Alzheimer's APP mRNA 5'-Untranslated Region: The Action of Paroxetine and Dimercaptopropanol

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970017-8

7 January 2021

10.1016/S1353-8020(08)70017-8

Identifiers

DOI

1 reference

18 August 2017

1 reference

PubMed ID

18267251